An Open-label, Multi-center, Phase I Study to Evaluate the Safety/tolerability and Pharmacokinetics of GFS202A in Advanced Solid Tumor Patients with Pre-cachexia or Cachexia
Latest Information Update: 03 Apr 2025
At a glance
- Drugs GFS202A (Primary)
- Indications Cachexia
- Focus Adverse reactions
- Sponsors GenFleet Therapeutics
- 03 Apr 2025 New trial record
- 12 Mar 2025 According to GenFleet Therapeutics media release, Receives Clinical Trial Approval from China's NMPA for GFS202A, a Bispecific Antibody Targeting GDF15 and IL-6, in a Phase I Study Treating Cancer Cachexia Patients.